VIB

Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round

March 24, 2025

Revolutionizing Protein Crop Cultivation in Europe

March 11, 2025

Tanai Therapeutics appoints Pieter Rottiers as Chief Executive Officer

January 22, 2025

VIB spin-off Muna Therapeutics Announces Strategic Alliance with GSK to Accelerate Development of Novel Treatments for Alzheimer’s Disease

December 6, 2024

VUB and VIB launch new Bio Incubator Brussels on VUB campus

Catalyst for collaboration and biotechnological innovation

December 5, 2024

Innovating in the world of oncology through RNA therapeutics

December 3, 2024

ExeVir Announces Michael Garrett as New Chief Executive Officer

Company developing antibody therapeutics against emerging viral threats

November 18, 2024

Zymofix secures €2 million to scale microbial solutions for sustainable agriculture and beyond

• Additional financing to advance proprietary fermentation technology • Looking to expand the team to support its rapid growth • Rebranded from N-Fix to Zymofix – learn more at Zymofix.com

November 12, 2024

Protealis Secures 1.2m EUR VLAIO grants to Advance Local High-Performing Legume Crop Innovations in Northern Europe

November 6, 2024

Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety

October 1, 2024

About VIB

VIB is a leading life sciences research institute based in Belgium, renowned for its work in medical sciences, plant biology, microbiology, artificial intelligence and biotechnology. VIB's mission is to push the boundaries of scientific discovery, transform it into disruptive biotech innovations and support the growth of the life sciences ecosystem in Flanders (Belgium). VIB is a partnership with Ghent University, Hasselt University, KU Leuven, University of Antwerp, and Vrije Universiteit Brussel.

VIB drives the translation of research discoveries into innovative products and technologies for patients, consumers and society. It does so by launching new spin-offs, licensing intellectual property to companies, engaging in dynamic partnerships and fostering talent development. VIB has created 39 spin-offs in the healthcare and agrifood sectors, attracting over €1.8 billion in equity investment and has partnered intensely with industry, generating over €350 million in income. VIB’s research has led to dozens of innovative products brought to market for medical, agriculture, and food applications, with many more in development. Seven of its spin-off companies have reached the clinical stage.

Learn more at www.vib.be.

Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round

Revolutionizing Protein Crop Cultivation in Europe

Tanai Therapeutics appoints Pieter Rottiers as Chief Executive Officer

VIB spin-off Muna Therapeutics Announces Strategic Alliance with GSK to Accelerate Development of Novel Treatments for Alzheimer’s Disease

VUB and VIB launch new Bio Incubator Brussels on VUB campus

Innovating in the world of oncology through RNA therapeutics

ExeVir Announces Michael Garrett as New Chief Executive Officer

Zymofix secures €2 million to scale microbial solutions for sustainable agriculture and beyond

Protealis Secures 1.2m EUR VLAIO grants to Advance Local High-Performing Legume Crop Innovations in Northern Europe

Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety

Contact us

Lies Vanneste

Investor Relations Manager, VIB

Get updates in your mailbox

About VIB

Contact